Arcutis Biotherapeutics (ARQT) Net Equity Issued and Repurchased (2020 - 2024)
Arcutis Biotherapeutics (ARQT) posted quarterly Net Equity Issued and Repurchased of $3.1 million for Q4 2024, little changed year-over-year from $3.1 million in Q1 2024, and down 98.08% quarter-over-quarter from $161.7 million in Q1 2024.
Arcutis Biotherapeutics (ARQT) Net Equity Issued and Repurchased (2020 - 2024) Analysis & Trends
Arcutis Biotherapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $3.1 million for Q4 2024.
- In Q4 2024, Net Equity Issued and Repurchased changed 0.0% year-over-year to $3.1 million; the TTM figure through Sep 2025 stood at $3.1 million (down 98.12% YoY), while the FY2024 annual figure was $161.7 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q4 2024 stood at $3.1 million, down from $161.7 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $207.5 million in Q1 2021, with the low at -$45000.0 in Q2 2022.
- The 5-year median for Net Equity Issued and Repurchased is $14.5 million (2022), against an average of $74.0 million.
- The sharpest annual moves came in 2022 and 2024: Net Equity Issued and Repurchased sank 93.01% in 2022, then changed 0.0% in 2024.
- Arcutis Biotherapeutics' Net Equity Issued and Repurchased stood at $128.4 million in 2020, then surged by 61.65% to $207.5 million in 2021, then tumbled by 100.02% to -$45000.0 in 2022, then surged by 6988.89% to $3.1 million in 2023, then changed by 0.0% to $3.1 million in 2024.
- Business Quant data shows ARQT's Net Equity Issued and Repurchased at $3.1 million in Q4 2024, $161.7 million in Q1 2024, and $3.1 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.10 Mn |
| Dec 31, 2024 | 3.10 Mn |
| Mar 31, 2024 | 161.68 Mn |
| Mar 31, 2024 | 161.68 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Jun 30, 2022 | -45,000.00 |
| Jun 30, 2022 | -45,000.00 |
| Mar 31, 2022 | 14.50 Mn |
| Mar 31, 2022 | 14.50 Mn |
| Mar 31, 2021 | 207.49 Mn |
| Mar 31, 2021 | 207.49 Mn |
| Dec 31, 2020 | 128.36 Mn |
| Dec 31, 2020 | 128.36 Mn |